Company intelligence / Profile preview

Achelois BioPharma

Redwood City, California, United Statesachelois.eu ↗

Ownership: Private
Development stage: Preclinical

Overview

Achelois BioPharma develops programmable immunotherapies using proprietary platforms to target complex human diseases. Their approach focuses on multivalent therapeutics designed to address multiple disease mechanisms simultaneously. No published clinical results as of the latest available information.[1][2][3]

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Multivalent therapeutics (including genetically engineered T cells and multivalent particles)Immunotherapy (GEM-T Cells)Genetically-programmed multivalent particles (MVPs)
Industry: Biotech

Drug pipeline

2 assets

GEM155/19 CAR-T

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

JLabs incubator program/investment partner[3]

Beyond the preview

Go deeper on Achelois BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Achelois BioPharma.

Explore the full profile